Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A study to assess Feasibility, efficacy, and safety of using dolutegravir/lamivu- dine (DTG/3TC) as a first-line regimen in a test-and-treat setting for newly diagnosed Patients living with HIV

Next Previous
X
Search
Trial Profile

A study to assess Feasibility, efficacy, and safety of using dolutegravir/lamivu- dine (DTG/3TC) as a first-line regimen in a test-and-treat setting for newly diagnosed Patients living with HIV

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 16 Dec 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dolutegravir/lamivudine (Primary)
  • Indications HIV-1 infections
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms STAT

    • Most Recent Events

    • 26 Oct 2022 Results assessing patient reported symptom burden through week 48, presented at the 16th International Congress on Drug Therapy and HIV Infection.
    • 21 Jul 2021 Results of 48-week end-of-study results presented at the 11th International AIDS Society Conference on HIV Science
    • 17 Jul 2021 According to ViiV Healthcare media release, results will be presented at the International AIDS Society Conference 2021 (IAS 2021)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top